Moteur de recherche d’entreprises européennes
Financement de l’UE (5 999 021 €) : Conditions comorbides du trouble déficitaire de l’attention / hyperactivité Hor 01/01/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Conditions comorbides du trouble déficitaire de l’attention / hyperactivité
Understanding mechanisms underlying comorbid disorders poses a challenge for developing precision medicine tools. Psychiatric disorders are highly comorbid, and are among the last areas of medicine, where classification is driven by phenomenology rather than pathophysiology. We will study comorbidity between the most frequent psychiatric conditions, ADHD, mood/anxiety, and substance use disorders, and a highly prevalent somatic disease, obesity. ADHD, a childhood-onset disorder, forms the entry into a lifelong negative trajectory characterized by these comorbidities. Common mechanisms underlying this course are unknown, despite their relevance for early detection, prevention, and treatment. Our interdisciplinary team of experts will integrate epidemiologic/genetic approaches with experimental designs to address those issues. We will determine disease burden of comorbidity, calculate its socioeconomic impact, and reveal risk factors. We will study biological pathways of comorbidity and derive biomarkers, prioritizing two candidate mechanisms (circadian rhythm and dopaminergic neurotransmission), but also leveraging large existing data sets to identify new ones. A pilot clinical trial to study non-pharmacologic, dopamine-based and chronobiological treatments will be performed, employing innovative mHealth to monitor and support patients’ daily life. Integration of findings will lead to prediction algorithms enhancing early diagnosis and prevention of comorbidity. Finally, we will screen to repurpose existing pharmacological compounds. Integrating complementary approaches based on large-scale, existing data and innovative data collection, we maximize value for money in this project, leading to insight into the mechanisms underlying this comorbidity triad with its huge burden for healthcare, economy, and society. This will facilitate early detection and non-invasive, scalable, and low-cost treatment, creating opportunities for substantial and immediate societal impact.
| Aarhus Universitet | 261 805 € |
| Academisch Ziekenhuis Groningen | 262 000 € |
| Concentris Research Management GmbH | 360 000 € |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | 326 996 € |
| HGC Healthcare Consultants GmbH | 150 000 € |
| Johann Wolfgang Goethe-Universitaet Frankfurt AM Main | 996 898 € |
| Karlsruher Institut Fuer Technologie | 466 913 € |
| Karolinska Institutet | 202 000 € |
| King's College London | 589 000 € |
| Stichting Radboud Universitair Medisch Centrum | 585 000 € |
| Stichting Radboud Universiteit | 0,00 € |
| Tartu Ulikool | 147 000 € |
| THE Research Foundation OF State University OF NEW York | 312 000 € |
| Universidad de Granada | 105 000 € |
| Universitat de Barcelona | 252 391 € |
| Universitatsklinikum Heidelberg | 339 658 € |
| Universitatsmedizin Rostock | 240 000 € |
| Universitetet I Bergen | 402 360 € |
https://cordis.europa.eu/project/id/667302
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.